The 3.2 Å Structure of a Bioengineered Variant of Blood Coagulation Factor VIII Indicates Two Conformations of the C2 Domain.

CONCLUSIONS: These improved structures yield a more confident model for next generation engineering efforts to develop FVIII therapeutics with longer half-lives, higher expression levels and lower immunogenicity. This article is protected by copyright. All rights reserved.
PMID: 31454152 [PubMed - as supplied by publisher]

Source: Thrombosis and Haemostasis - August 26, 2019 Category: Hematology Authors: Smith IW, d'Aquino AE, Coyle CW, Fedanov A, Parker ET, Denning G, Spencer HT, Lollar P, Doering CB, Spiegel PC Tags: J Thromb Haemost Source Type: research